Comparative Pharmacology
Head-to-head clinical analysis: LARIN 1 5 30 versus LOARGYS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN 1 5 30 versus LOARGYS.
LARIN 1.5/30 vs LOARGYS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
LOARGYS is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
100 mg orally twice daily.
None Documented
None Documented
Ethinyl estradiol: 13-19 hours; Norethindrone: 7-9 hours. Steady-state achieved in ~5-7 days.
Terminal elimination half-life: 12-18 hours (prolonged in renal impairment).
Renal (40% as metabolites, <10% unchanged); fecal (50% as metabolites); biliary (minor).
Primarily renal (70-80% unchanged; 10-15% as metabolites); biliary/fecal (5-10%).
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive